2016
Effects of Physical Activity on DNA Methylation and Associations with Breast Cancer
Yu H, Irwin M. Effects of Physical Activity on DNA Methylation and Associations with Breast Cancer. Energy Balance And Cancer 2016, 11: 251-264. DOI: 10.1007/978-3-319-41610-6_11.Peer-Reviewed Original ResearchDNA methylationTumor suppressor genePhysical activityEpigenetic regulationSuppressor geneCancer riskGenome-wide methylationBetter patient survivalBreast cancer patientsPro-inflammatory cytokinesBreast cancer riskSex steroid hormonesLower cancer riskMitogenic growth factorsEntire genomeMolecular mechanismsInsulin resistancePatient survivalCancer patientsMethylationMore profound impactsCancer preventionBreast cancerDisease outcomeHealthy individuals
2011
Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women
Qian B, Zheng H, Yu H, Chen K. Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research And Treatment 2011, 130: 217. PMID: 21562710, DOI: 10.1007/s10549-011-1552-9.Peer-Reviewed Original ResearchConceptsBreast cancer riskIGFBP-3 genotypesIGFBP-3 single nucleotide polymorphismsCancer riskChinese womenIGFBP-3Single nucleotide polymorphismsBreast cancerBreast tumorsTumor samplesLocal breast tissuesBreast cancer patientsIGF-I activityER-negative tumorsUnconditional logistic regressionCase-control studyFresh tumor samplesAge-matched controlsWilcoxon rank sum testRank sum testHigher peptide levelsIGFBP-3 geneIGF-I geneNegative tumorsCancer patients
2008
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stage
2006
High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer
Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson L, DeBenedetti A, Abreo F, Turnage R, McDonald J, Li B. High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer. Annals Of Surgery 2006, 243: 684-692. PMID: 16633004, PMCID: PMC1570543, DOI: 10.1097/01.sla.0000216770.23642.d8.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorCancer-related deathWorse clinical outcomesBreast cancer patientsHigh eIF4E overexpressionMicrovessel densityEIF4E overexpressionCancer specimensHigh eIF4ENodal statusClinical outcomesVEGF elevationMVD countCancer patientsCancer recurrenceBreast cancerStage IShorter disease-free survivalClinical surveillance protocolLow eIF4E overexpressionDisease-free survivalHighest cancer-related deathsHigher VEGF levelsTumor microvessel densityBreast cancer specimensUpregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients
Wolfort R, Chu Q, Turnage R, Yu H, Nuthalapaty S, De Benedetti A, Li B. Upregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients. Journal Of Surgical Research 2006, 130: 218-219. DOI: 10.1016/j.jss.2005.11.161.Peer-Reviewed Original Research
2004
IGF‐I and breast cancer: A meta‐analysis
Shi R, Yu H, McLarty J, Glass J. IGF‐I and breast cancer: A meta‐analysis. International Journal Of Cancer 2004, 111: 418-423. PMID: 15221971, DOI: 10.1002/ijc.20233.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceIGFBP-3 levelsLevels of IGFIGF-binding proteinsBreast cancer riskStandardized mean differencePremenopausal womenBreast cancerIGFBP-3Cancer riskBreast cancer patientsEffects of IGFPostmenopausal womenPostmenopausal groupPremenopausal groupHigher IGFCancer patientsClinical studiesEpidemiologic studiesParacrine mechanismsIGFOverall associationMean differenceCancerWomenGenetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.
Ren Z, Cai Q, Shu X, Cai H, Li C, Yu H, Gao Y, Zheng W. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiology Biomarkers & Prevention 2004, 13: 1290-5. PMID: 15298948, DOI: 10.1158/1055-9965.1290.13.8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionBase SequenceBiomarkers, TumorBreast NeoplasmsCase-Control StudiesChinaConfidence IntervalsFemaleGenetic Predisposition to DiseaseHumansIncidenceInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsMiddle AgedMolecular Sequence DataOdds RatioPolymerase Chain ReactionPolymorphism, GeneticPopulation SurveillanceReference ValuesRisk AssessmentConceptsInsulin-like growth factorIGFBP-3 protein levelsBreast cancer riskBreast cancerVariant allelesIGFBP3 polymorphismsIGFBP-3IGFBP3 geneCancer riskElevated riskRisk genotypesActions of IGFsIncident breast cancer patientsChinese womenIGFBP-3 levelsIGF binding proteinBreast cancer patientsGenetic polymorphismsIGFBP-3 proteinProtein levelsCase-control studyDose-response mannerCancer patientsOdds ratioPolymorphism A
2001
Polymorphic CA repeats in the IGF-I gene and breast cancer
Yu H, Li B, Smith M, Shi R, Berkel H, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Research And Treatment 2001, 70: 117-122. PMID: 11768601, DOI: 10.1023/a:1012947027213.Peer-Reviewed Original ResearchConceptsBreast cancer patientsBreast cancerIGF-I geneCancer patientsCA repeatsUnconditional logistic regression analysisInsulin-like growth factorRole of IGFHigher odds ratioLogistic regression analysisHigher plasma IGFIGF-I genotypeBreast cancer cellsIGF-I polymorphismMenopausal statusPeripheral bloodPlasma IGFOdds ratioMedian numberNumber of CaCancerLarger studyAlcohol usePotent mitogenIGFFree insulin‐like growth factor‐I and breast cancer risk
Li B, Khosravi M, Berkel H, Diamandi A, Dayton M, Smith M, Yu H. Free insulin‐like growth factor‐I and breast cancer risk. International Journal Of Cancer 2001, 91: 736-739. PMID: 11267989, DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1111>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsIGF-I receptorInsulin-like growth factorFree IGFIGFBP-3Action of IGFBreast cancer patientsTotal IGFBreast cancer riskBreast cancerIGF-IICancer patientsPlasma levelsCancer riskFree insulin-like growth factorRace-matched healthy controlsFree IGF-I levelsConditional logistic regression analysisGrowth factorIGF-I levelsIGF binding proteinBinding of IGFHigher plasma levelsLogistic regression analysisHigher plasma IGFAnti-apoptotic effects
2000
Patient Compliance Is Critical for Equivalent Clinical Outcomes for Breast Cancer Treated by Breast-Conservation Therapy
Li B, Brown W, Ampil F, Burton G, Yu H, McDonald J. Patient Compliance Is Critical for Equivalent Clinical Outcomes for Breast Cancer Treated by Breast-Conservation Therapy. Annals Of Surgery 2000, 231: 883-889. PMID: 10816632, PMCID: PMC1421078, DOI: 10.1097/00000658-200006000-00013.Peer-Reviewed Original ResearchConceptsLocal failure rateEarly breast cancerClinical trialsBreast cancerClinical outcomesPatient complianceHigh local failure rateEarly-stage breast cancerKaplan-Meier survival analysisDisease-free survivalEquivalent clinical outcomesBreast cancer patientsBreast conservation therapyLog-rank testClinical trial resultsClinical trial dataStage of cancerFisher's exact testRate of complianceFailure rateEducation levelOverall survivalRadical mastectomyNoncompliant patientsRetrospective reviewClinical implications of prostate-specific antigen in men and women.
Yu H. Clinical implications of prostate-specific antigen in men and women. Journal Of Gender-Specific Medicine 2000, 3: 45-8, 53. PMID: 11253246.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPresence of PSAClinical implicationsLevels of PSABreast tissueBreast cancer patientsBreast cancer riskSex steroid hormonesValuable tumor markerExcess androgenFavorable prognosisPregnant womenBreast fluidCancer patientsNipple aspiratesProstate cancerClinical studiesCancer riskTumor markersCyst fluidFemale serumSteroid hormonesConcentration of PSAMore studiesWomen
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Foekens J, Diamandis E, Yu H, Look M, Gelder M, Putten W, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal Of Cancer 1999, 79: 888-894. PMID: 10070886, PMCID: PMC2362687, DOI: 10.1038/sj.bjc.6690142.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm StagingPostmenopausePredictive Value of TestsPremenopauseProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival AnalysisTamoxifenTime FactorsConceptsLevels of PSAProstate-specific antigenPrimary breast cancerRecurrent breast cancerBreast tumor cytosolsBreast cancerRecurrent diseaseEnzyme-linked immunosorbent assayTamoxifen therapyPoor responseTumor cytosolsAge/menopausal statusFirst-line tamoxifen therapyHormone receptor-negative tumorsSteroid hormone receptor statusDisease-free intervalSite of relapseCox multivariate analysisHormone receptor statusReceptor-negative tumorsClassical prognostic factorsPost-menopausal patientsRate of relapseBreast cancer patientsStart of treatment
1998
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients
Levesque M, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis E. Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal Of Cancer 1998, 79: 147-152. PMID: 9583729, DOI: 10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceAntibody SpecificityBreast NeoplasmsCarcinoma, Ductal, BreastCombined Modality TherapyDisease-Free SurvivalFemaleFluorescent Antibody TechniqueHumansLymphatic MetastasisMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsPrognosisReceptors, EstrogenReceptors, ProgesteroneRecurrenceSensitivity and SpecificityTime FactorsTumor Suppressor Protein p53ConceptsP53 proteinItalian breast cancer patientsProgesterone receptor expression statusMultivariate Cox regression analysisP53-negative patientsP53-positive patientsReceptor expression statusDisease-free survivalLymph node statusSteroid hormone receptor analysisCox regression analysisBreast cancer patientsEstrogen receptor expressionHormone receptor analysisCM-1 antibodySensitive immunofluorometric assayBreast cancer prognosisP53 protein accumulationOverall survivalPatient ageIndependent predictorsHistologic typeNode statusPrognostic valueShort patients
1996
Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients
Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis E. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. British Journal Of Cancer 1996, 73: 386-390. PMID: 8562347, PMCID: PMC2074443, DOI: 10.1038/bjc.1996.66.Peer-Reviewed Original ResearchConceptsCK-BB levelsCK-BBTumor cytosolsEstrogen receptor-negative cancersEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancer patientsRisk of deathReceptor-negative cancersRisk of relapseBreast tumor cytosolsHistological typeClinicopathological variablesPatient survivalPrognostic indicatorTumor stageAggressive tumorsCancer patientsProgesterone receptorUnivariate analysisHigh riskBB groupIsoenzyme levelsPatientsBreast tumors
1995
Prostate-specific antigen in serum of women with breast cancer
Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque M, Diamandis E. Prostate-specific antigen in serum of women with breast cancer. British Journal Of Cancer 1995, 72: 728-731. PMID: 7545417, PMCID: PMC2033864, DOI: 10.1038/bjc.1995.401.Peer-Reviewed Original ResearchConceptsSerum prostate-specific antigenProstate-specific antigenBreast cancer patientsBreast cancerPSA levelsCancer patientsTumor cytosolsBreast tumorsPSA concentrationFree prostate-specific antigenSerum of womenFavorable prognostic indicatorSerum PSA levelsNormal male serumFemale breast tumorsBreast cancer diagnosisPresurgical seraPrognostic indicatorSurgical removalNormal breastMale serumCancerSerumCancer diagnosisTumorsProstate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H, Giai M, Diamandis E, Katsaros D, Sutherland D, Levesque M, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 1995, 55: 2104-10. PMID: 7538047.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSABreast cancerCox proportional hazards regression modelEstrogen receptor-negative patientsEstrogen receptor-positive tumorsProportional hazards regression modelsIndependent favorable prognostic markerReceptor-negative patientsNode-positive patientsFavorable prognostic indicatorSurvival of patientsReceptor-positive tumorsRelapse-free survivalBreast cancer patientsFemale breast cancerHazards regression modelsEarly disease stagesFavorable prognostic markerProstatic epithelial cellsPSA statusBetter prognosisPositive tumorsPrognostic valueDisease stage
1994
Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age
Yu H, Diamandis E, Sutherland D. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clinical Biochemistry 1994, 27: 75-79. PMID: 7520846, DOI: 10.1016/0009-9120(94)90015-9.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSAMale breast tumorsBreast tumor cytosolsBreast tumorsPatient agePositivity rateTumor cytosolsImmunoreactive prostate-specific antigenProstate-specific antigen levelPR-positive tumorsBreast cancer patientsSubset of tumorsCancerous prostatic tissueSteroid hormone receptorsAntigen levelsCancer patientsProgesterone receptorBreast cancerProstatic tissuePR actionEstrogenTumorsHormone receptorsSpecific markers